-

12:45:14 AM

SLGL Stock News

SLGL - Sol-Gel Technologies Ltd

05/17/22 7:00 AM

Nasdaq : SLGL

conferenceslow float

Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the

RHEA-AI

neutral

05/13/22 7:00 AM

Nasdaq : SLGL

earningslow float

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

FDA approval for EPSOLAY ® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year ; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launch ed in the U.S. market in April for the topical

RHEA-AI

very positive

04/25/22 7:00 AM

Nasdaq : SLGL

fda approvallow float

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma set to commercialize EPSOLAY in the U.S. under exclusive license NESS ZIONA, Israel and ZUG,

RHEA-AI

very positive

04/14/22 8:30 AM

Nasdaq : SLGL

low float

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acne Sol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO ® in the U.S. at the Annual Meeting of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO is now available for

RHEA-AI

neutral

03/30/22 7:00 AM

Nasdaq : SLGL

earningslow float

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Galderma launched TWYNEO ® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 months in exchange for the transfer of its rights

RHEA-AI

positive

03/25/22 11:00 AM

Nasdaq : SLGL

low float

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products

RHEA-AI

neutral

12/22/21 4:05 PM

Nasdaq : SLGL

conferenceslow float

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the

RHEA-AI

neutral

12/21/21 7:00 AM

Nasdaq : SLGL

low float

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying,

RHEA-AI

neutral

11/11/21 7:00 AM

Nasdaq : SLGL

earningslow float

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel attains a profitable quarter , reporting total revenues of $ 8.8 million , net income of $1.3 million and EPS of $0. 06 Recently obtained FDA approval of TWYNEO ® trigger s a $ 3.5 million milestone payment from Galderma , and , together with the $4.0 million down payment from Galderma , a

RHEA-AI

very positive

11/09/21 7:05 AM

Nasdaq : SLGL

conferenceslow float

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will

RHEA-AI

neutral

SLGL Data

IndustryMedicinal and Botanical Manufacturing
Websitewww.sol-gel.com
CeoAlon Seri-Levy
Security nameSol-Gel Technologies Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees65
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
AddressWeizmann Science Park
StateNess Ziona
City7 Golda Meir
Zip7403650
CountryIsrael
Phone97289313433

About Sol-Gel Technologies Ltd

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.